ISSUE 1395
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Most experts agree that lifestyle modifications and metformin (Glucophage, and others) should be used first to treat patients with type 2 diabetes.1 If metformin alone fails to control hyperglycemia, there is no general agreement on which drug should be added next. A recent article in The Medical Letter offered some support for a sulfonylurea.2 Three recent trials published in The Lancet favored the long-acting basal insulin glargine, the glucagon-like peptide (GLP-1) analog exenatide, and the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, respectively.3,4,5 Some of the advantages and disadvantages of these and other available agents are listed in Table 1.
RECOMMENDATIONS — When metformin does not adequately control hyperglycemia, addition of a sulfonylurea appears
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1395b
Electronic, downloadable article - $45